“One hundred years ago, at the time when Haematologica was first published, there was practically no treatment for the hemophilias or for the other inherited coagulation disorders. Whole blood was the only treatment approach available and this was of poor clinical efficacy, such that the life expectancy of hemophiliacs was 10-15 years, even in the most favorable circumstances.The success story of hemophilia care first began in the 1970s, when the availability of plasma-derived concentrates of coagulation factor VIII (FVIII) and factor IX (FIX) provided efficacious treatment of bleeding in patients with hemophilia A and B. This positive scenario was consolidated in terms of greater safety and availability in the 1990s, when the first recombinant coagulation factors were produced. This meant that, instead of only treating episodic bleeding events, prophylaxis regimens could be implemented as a preventive measure.  So, even until the 1960s, the life expectancy of patients with hemophilia was no more than 20-30 years.  Today success is way ahead.”

NIH – National Library of Medicine (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049365/)